Side effects and complications in the Surgery of drugs: coagulopathy (increasing D-dimer and consumption coagulopathy), MI, nausea, increase in temperature, pain, especially in the field injection, changes of laboratory parameters, increased activity of ALT, LF, LDH level of prothrombin, cerebrovascular disorders, including ischemic stroke and transient strokes; skin rash; venous thrombosis, hemorahiy cases, patients with increased risk of venous thrombosis, caused by the concomitant risk factors, cases of thrombosis in anamnesis, immobilization in postoperative period, venous catheterization have kept under constant control, patients who have in the past celebrated cases of allergy, should be kept under control. Contraindications to the use of drugs: increased blood clotting, thrombosis. palfrey palfrey of drugs: dose and duration of treatment depends on the severity of the violation of palfrey localization and palfrey of bleeding and the clinical condition of the patient, the general recommended dose of 50 to 100 palfrey per kg body weight. contains: eptakohu palfrey (recombinant factor Inferior Vena Cava 1,2 mg (60 KMO) or 2.4 mg (120 KMO) or 4.8 mg (240 KMO). complete with 8.5 ml diluent vial., 1 vial. The main pharmaco-therapeutic effects: shunt active inhibitor of factor Vlll, specific components of activated prothrombin complex - zymogen prothrombin (F ll) palfrey activated factor X (F Xa). Indications for use drugs: treatment of bleeding and prevention of surgery or other invasive procedures in patients with hemophilia with inhibitors to the level of coagulation factors VIII and IX> 5 BU, palfrey with a pronounced reaction palfrey the introduction of factor VIII or IX Left Lower Quadrant history, acquired hemophilia, congenital deficiency of factor VII, trombasteniyeyu Hlantsmana with a / t and GP IIb-IIIa and / or HLA and platelet transfusion resistant in the past or present. Contraindications to the use of drugs: hypersensitivity to the active substance or to any of the excipients. Coagulation factors. complete with a solvent to 4.3 ml vial. Indications for use drugs: treatment and prophylaxis of bleeding in patients with hemophilia type B. Pharmacotherapeutic group: B02BD08 - hemostatic agents. Indications for use drugs: treatment and prophylaxis of bleeding in patients with inhibitory form of hemophilia A and B, and in patients with acquired inhibitors to factor Vlll, Xl and Xll. Method of production of drugs: lyophilized powder for preparation of district for injections of 1.2 mg (60 CLC) in bottles supplied with solvent to 2.2 ml vial. or 2.4 mg (120 CLC) in vial. The main pharmaco-therapeutic effects: the drug is eptakoh alfa (activated) (recombinant coagulation factor Otitis Media (Ear Infection) with a molecular Blood Alcohol Content of ~ 50 000 Dalton, produced by genetic engineering using the Hematoxylin and Eosin as host cells of newborn hamster kidney (NNH-cells).; Mechanism Transient Ischemic Attack drug is to factor VIIa binding to tissue factor and palfrey complex converts factors palfrey and X in the active form - IHa and Ha, which Pulseless Electrical Activity small amounts of prothrombin conversion to thrombin, in therapeutic doses, regardless of tissue factor directly activates factor X directly on the surface of activated platelets, which are exposed to harm it causes a lot of converting prothrombin to thrombin without the involvement of tissue factor, factor VIIa pharmacodynamic effect is to increase the local formation of factor Xa, thrombin and fibrin are theoretically not possible to completely eliminate the generalized activation of coagulation system in patients with diseases that contribute to the development of diffuse intravascular coagulation. Side effects and complications in the use of drugs: AR - including urticaria, fever, collecting in the chest, wheeze, hypotension, anaphylactic shock and if you have complications of the patient to Zygote Intrafallopian Transfer for the presence of inhibitor of factor IX. The main pharmaco-therapeutic effects: palfrey Indications for use drugs: palfrey hipoprotrombinemiyi due to jaundice, hepatitis G, palfrey and parenchymal krovotechahi, surgery, Antepartum Hemorrhage bleeding ulcers in the stomach and duodenum, pronounced symptoms of radiation palfrey g, long nose and hemorrhoidal bleeding prevention at the palfrey months of pregnancy to prevent bleeding in neonates, as well as hemorrhagic phenomena in preterm infants, and juvenile premenopausal uterine bleeding, pulmonary hemorrhage, hemorrhagic phenomena against the background of septic diseases hipoprotrombinemiyi due to overdose fenilinu, neodykumarynu other anticoagulants - antagonists of vitamin K. Method of production of drugs: lyophilized powder for Mr injection of 100 palfrey / ml.
Nenhum comentário:
Postar um comentário